From Medscape Diabetes & Endocrinology

ENDO 2016: The Endocrine Society Annual Meeting

April 01 - 04, 2016; Boston, Massachusetts

April 01 - 04, 2016 Boston, Massachusetts

More Studies Support Testosterone CV Safety, Debate Continues Two new analyses suggest that there is no increased risk for venous thromboembolism or cardiovascular events with testosterone treatment, but experts say the definitive trial has yet to be done.
Medscape Medical News, Mar 16, 2015
No Link Seen Between Hormone Replacement Therapy, Mortality A systematic review and meta-analysis of more than 52,000 postmenopausal women in 43 randomized controlled trials found no association between hormone replacement therapy and death from any cause.
Medscape Medical News, Mar 7, 2015
Endocrine Disruptors Cause Range of Diseases; Cost 157 Billion Euros A new EU analysis suggests a wide range of neurologic, endocrinologic, and reproductive abnormalities from chemicals used in everyday products such as pesticides, cosmetics, and flame retardants.
Medscape Medical News, Mar 6, 2015

Medscape Diabetes© WebMD, LLC

Perspectives

Live Blog

News and Views from ENDO 2016 Coverage of key advances and expert reactions as they happened at the meeting.

Medscape Board at the Podium

Vivian Fonseca, MD
Tulane University, New Orleans, Louisiana

Presentation: Endocrine Health Disparities in Unusual Situations
Date: April 2, 2016
Anne Peters, MD
Anne Peters, MD

Presentation: Diabetes Technology: An Endocrine Society Clinical Practice Guideline
Date: April 1, 2016

Previous Coverage